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Abstract Chronic neurodegenerative disorders including dementias, as Alzheimer’s disease (AD) and movement disorders, as Parkinson’s disease (PD) are strongly increasing worldwide. Up to now, very little is known 
about their biochemical mechanism and no effective therapeutic strategies are available to face brain functionality deterioration.
A very intriguing hypothesis actively under investigation is referred as “microbiota-gut-brain axis”. It suggests that human gut microbial 
community might impact central nervous system functionality through a bidirectional interaction that potentially might play also a key 
role in neurodegenerative disorders. Here we present a novel technological project, named MINERVA supported by the European 
Research Council (ERC) Programme, that aims, by using an innovative bioengineering approach, at evaluating microbiota impact on 
brain functionality. MINERVA goal is to develop a cutting edge technological platform, based on organ on chip microfluidic device, 
to model the main players of the microbiota-gut-brain axis. The final aim of MINERVA is to investigate the role of microbiota on brain 
functionality in physiological but also in pathological neurodegenerative conditions in order to improve the knowledge in the field and 
open the way to potential novel therapeutic microbiota-based approach for neurodegenerative disorders. 
MINERVA: the technological project to boost 
research on the microbiota-gut-brain axis in 
chronic neurodegenerative disorders
MICROBIOTA-GUT-BRAIN AXIS: A FOCUSED OVERVIEW 
Alzheimer’s (AD) and Parkinson’s (PD) disease are severe 
chronic neurodegenerative pathologies. ADfeatures memory 
loss, followed by behavioral changes and impairment in 
everyday life. PD is characterized by movement disturbances, 
but it is not unusual the presence of dementia (1). An 
extremely interesting hypothesis is that the intestinal microfl ora 
(collectively named “microbiota”) is a key player in chronic 
neurodegeneration. A relation 
between gut microbiota 
and brain, referred to as 
“microbiota-gut-brain axis”, 
was fi rstly hypothesized more 
than 100 years ago by the 
Russian embryologist Elie 
Metchnikoff: he surmised that a 
healthy microbiota could help 
counteracting aging and that 
some bacterial strains (what 
we call today “probiotics”) 
found in sour milk and yogurt 
would increase longevity 
(2). Literature shows that 
Metchnikoff’s fi ndings have 
been recently re-evaluated, 
becoming a new, exciting 
hypothesis in neuroscience: 
up to now, the papers on a 
possible role of gut microbiota on brain or AD/PD increased 
impressively, going from 8 in 2008 to 842 in September 2017, 
with 258 articles published in 2016 only (Table 1; source: 
PubMed).  Many proposals dealing with the microbiota have 
been granted in the last 6 years: in 2011 and in 2012, the 
Michael J. Fox Foundation (USA) funded two grants on gut 
microbiota effect on PD, while “MYNEWGUT” was fi nanced 
in Europe and it deals with diet, microbiota and its impact 
on brain development. The Human Microbiome Project-HMP 
(USA) was designed to sample, 
determine and quantify all 
human-associated microbiota; 
MetaHIT in Europe, is focused 
on intestinal microbiota; 
Eldermet in Ireland, is a national 
project associated with the 
large European project “NU-
AGE” (the latter centered on 
the elderly) aimed at assessing 
the association between gut 
microbiota, food and health in 
the elderly. Very recently, the 
H2020 EU Programme granted 
the “AD-GUT” project, where 
for the fi rsttime microbiota 
composition will be manipulated 
in AD patients to evaluate how 
this affect the diagnosis and 
progression of the disease. 
Table 1. Number of published articles on the microbiota-gut-
brain axis in the last 10 years, with a focus on Alzheimer’s 
disease and Parkinson’s disease. (source: PubMed;  keywords: 
“microbiota gut brain”; “microbiota gut brain Alzheimer’s 
disease”; “microbiota gut brain Parkinson’s disease”.
Note: the sum of published article/year exceeds the single 
search from 2008 to 2017 (842, 37 and 38, respectively) as some 
papers in the single year search are counted twice (year of 
e-pub and printed version).
49Agro FOOD Industry Hi Tech - vol. 28(6) - November/December 2017
but they are performed with 
standard techniques that rely 
on 2D static immortalized cell 
models and their treatment 
with bacterial-derived 
molecules, a model that 
is very far from the real in 
vivo situation. In this setting, 
the availability of valuable 
innovative technological tools 
to consolidate the potential 
mechanisms by which the 
microbiota impacts the brain 
functionality might greatly 
help in overcoming the current 
limitations of in vitro and in 
vivo tools (16). Actually, some 
interesting dynamic digestion model that involves microbiota 
component and reliably reproduce some key features of 
the human digestive tract are available, in particular: the 
Simulator of Human Intestinal Microbial Ecosystem (SHIME™ 
and M-SHIME™) (17); the TNO Gastro-Intestinal Model (TIM) 
(18); HUMIX (19). However, the study of the impact of gut 
microbiota modifications on brain functionality is far from 
being their aim.
MINERVA: AN ERC TECHNOLOGICAL PROJECT TO EVALUATE 
MICROBIOTA IMPACT ON BRAIN FUNCTIONALITY
Recently, an ERC Consolidator project named “Microbiota-
Gut-Brain engineered axis to evaluate microbiota impact 
on brain functionality” (acronym: MINERVA, ERC-CoG-2016 
- Proposal 724734), was funded and aims at designing the first 
complete “microbiota-gut-brain” axis physical model by using 
a bioengineering approach. This innovative platform relies on 
three compartments, based on state-of-the-art miniaturized, 
optically accessible microfluidic devices, hydraulically 
connected to reproduce in 
vitro the microbiota-gut-brain 
axis connection (Figure 1). In 
the MINERVA platform, human 
microbiota will be cultured in 
the “Microbiota-compartment” 
and the secreted molecules 
(the so called “secretome”) 
transported to the “Gut-
compartment” where gut 
epithelial cells and cells 
from the immune system will 
metabolize them as occurs 
in vivo. The resulting modified 
secretome will reach the 
“Brain-compartment”, built up 
by a complete blood-brain 
barrier in vitro model followed 
by two exhaustive 3D human 
brain cell models, featuring the 
three main populations of brain 
cells: neurons, astrocytes and 
microglia. In the first model, 
the cells will be co-cultured, to 
recapitulate brain cell-to-cell 
contacts; in the second model, 
NEURODEGENERATIVE 
DISORDERS AND MICROBIOTA 
IN LITERATURE
We have already several 
studies addressing the 
role of gut microbiota in 
(AD) or (PD) disease. For 
example, Bhattacharjee et 
al that described a number of 
evidences supporting microbiota-
AD relationship (3). In addition, 
Wang et al reported a role 
of the intestinal microbiota 
in the protective activities of 
polyphenols in AD (4), and a 
similar conclusion was drawn 
in a mouse model of  neurodegeneration (SAMP8 mice) (5). 
A direct action of microbiota on mechanisms involved in 
AD was reported by Minter et al, that suggested in mice  a 
regulation by the gut microbiota community of host innate 
immunity mechanisms, with an impact on inflammation 
and amyloidosis (6). Many other researchers reported a 
link between gut microbiota and AD in animal models 
(7-10). A very important finding came from a seminal work 
in human patients, where it was reported an increase of 
a pro-inflammatory microbiota in patients with cognitive 
impairment and brain amyloidosis (11). As for PD, researchers 
have already found a different microbiota composition 
in PD patients in comparison to controls, (12-14), while PD 
animal models point to a role of microbiota in clinical signs, 
as reported by Sampson et al, whose findings suggested that 
gut bacteria regulate movement disorders (15).
CURRENT AND INNOVATIVE MODELS TO STUDY THE IMPACT OF 
MICROBIOTA ON BRAIN
Currently the main 
experimental findings on 
microbiota-gut-brain axis 
impact on brain functionality, 
and in particular on AD/PD, rely 
mostly on in vivo assessments 
in rodent models, that allow 
to investigate the whole-body 
response to selected stimuli. 
Some of them have been used 
in particular to asses microbiota 
role in neurodegenerative 
disorders such as AD and PD 
(Table 2). However, they have 
several limitations: (a) rodent’s 
microbiota is very different from 
the human one, (b) even if we 
transplant human microbiota 
in rodents, residual murine or 
environmental contamination is 
a major issue, and (c) they are 
expensive, lab-intensive and 
do not allow a strict control on 
microbiota composition once 
inoculated. Many papers are 
also based on in vitro studies, 
Figure 1. MINERVA platform: it is based on three main 
compartments, representing the microbiota, the gut, and 
the brain that hosts five optically accessible, organ-on-chip 
microfluidic devices. Each device hosts advanced in vitro cell 
models to model the main players of the microbiota-gut-brain axis: 
the microbiota; the gut epithelium; the immune system; the blood 
brain barrier; the brain.
Table 2. Examples of current models to address the role of gut 
microbiota in Alzheimer’s and Parkinson’s neurodegenerative 
disease.
6. Minter MR, Zhang C, Leone V, et al. Antibiotic-induced 
perturbations in gut microbial diversity influences neuro-
inflammation and amyloidosis in a murine model of Alzheimer’s 
disease. Sci Rep. 2016;6:30028. 
7. Shen L, Liu L, Ji HF. Alzheimer’s Disease histological and 
behavioral manifestations in transgenic mice correlate with 
specific gut microbiome state. J Alzheimers Dis. 2017;56:385-
390. 
8. Harach T, Marungruang N, Duthilleul N, et al. Reduction of 
Abeta amyloid pathology in APPPS1 transgenic mice in the 
absence of gut microbiota. Sci Rep. 2017;7:41802.
9. Wu SC, Cao ZS, Chang KM, et al. Intestinal microbial dysbiosis 
aggravates the progression of Alzheimer’s disease in 
Drosophila. Nat Commun. 2017;8:24. 
10. Bonfili L, Cecarini V, Berardi S, et al.  Microbiota modulation 
counteracts Alzheimer’s disease progression influencing 
neuronal proteolysis and gut hormones plasma levels. Sci Rep. 
2017;72426. 
11. Cattaneo A, Cattane N, Galluzzi S, et al.  Association of brain 
amyloidosis with pro-inflammatory gut bacterial taxa and 
peripheral inflammation markers in cognitively impaired elderly. 
Neurobiol Aging. 2017;49:60-68. 
12. Petrov VA, Saltykova IV, Zhukova IA, et al.  Analysis of gut 
microbiota in patients with Parkinson’s Disease. Bull Exp Biol 
Med. 2017;162:734-737. 
13. Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids 
and gut microbiota differ between patients with Parkinson’s 
disease and age-matched controls. Parkinsonism Relat Disord. 
2016;32:66-72. 
14. Scheperjans F, Aho V, Pereira PA, et al.  Gut microbiota are 
related to Parkinson’s disease and clinical phenotype. Mov 
Disord. 2015;30:350-358. 
15. Sampson TR, Debelius JW, Thron T, et al. Gut Microbiota 
Regulate Motor Deficits and Neuroinflammation in a Model of 
Parkinson’s Disease. Cell. 2016;167:1469-1480.
16. Fritz JV, Desai MS, Shah P et al. Microbiome from meta-omics 
to causality: experimental models for human microbiome 
research. Microbiome 2013;1:14.
17. Marzorati M, Pinheiro I, Van den Abbeele P et al. An in vitro 
technology platform to assess host-microbiota interactions in 
the gastrointestinal tract. Agro FOOD Industry Hi-Tech 2012;23: 
8-11. 
18. Minekus M, in: The Impact of Food Bioactives on Health-in vitro 
and ex vivo models, Editors: Kitty Verhoeckx, Paul Cotter, Iván 
López-Expósito, Charlotte Kleiveland, Tor Lea, Alan Mackie, 
Teresa Requena, Dominika Swiatecka, Harry Wichers, ISBN: 978-
3-319-15791-7 (Print) 978-3-319-16104-4 (Online), pag: 37-46.
19. Shah P, Fritz JV, Glaab E, et al. A microfluidics-based in vitro 
model of the gastrointestinal human–microbe interface. Nature 
Communications 7:11535.
each cell type will be cultured individually to let explore the 
microbiota’s effect on each cell type. MINERVA platform 
will be functionally and biologically validated using an 
approach at increasing complexity, to finally assess 
neural cell response once exposed to human complete 
microbiota from (a) healthy donors, and (b) Alzheimer’s 
disease (AD) patients. MINERVA has the potential to fill the 
gap existing in current tools in the field of microbiota-gut-
brain axis at the boundaries between in vitro and in vivo 
models, to deep our knowledge in the field and suggest 
innovative strategies to be tested after the approval 
of clinical studies enrolling AD/PD cases that ultimately 
will demonstrated the impact of microbiota control in 
neurodegeneration. 
CONCLUSIONS
The fundamental concept of an interaction of gut 
microbiota with the nervous system has been revisiting in 
recent years: the main novelty is the search for a causal link 
between microbiota composition or metabolism and the 
molecular determinants of pathologies as Alzheimer’s or 
Parkinson’s disease, mostly considered up to now as based 
on brain autonomous mechanisms. We have very limited 
knowledge in this field but studies and models are under 
development. This hopefully will boost the perspective 
of a clinical translation, as the microbiota-brain relation 
would represent a breakthrough also from the therapeutic 
point of view: human microbiota composition is dynamic 
and tunable by diet and probiotics, a very common tool 
in medicine, for instance in association with antibiotics 
therapy.
It is out of doubt that the challenge is complex and only 
a multidisciplinary approach based on fruitful discussion 
among neuroscience, immunology, gastroenterology 
and bioengineering will be successful and MINERVA might 
represent a first challenge on this way.
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